NCT06083922 2026-04-16
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
25 trialsNCT06152575 2026-04-16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT05623020 2026-04-15
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT05736419 2026-04-08
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04566328 2026-04-03
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06918002 2026-04-02
ElLen
Intergroupe Francophone du Myelome
Phase 3 Recruiting
NCT06413498 2026-03-27
iMMagine-3
Gilead Sciences
Phase 3 Recruiting
NCT05519085 2026-03-24
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT05272826 2026-03-18
BOREALIS
Canadian Myeloma Research Group
Phase 2 Recruiting
NCT03590171 2026-03-17
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
Phase 2 Recruiting
NCT06158841 2026-03-13
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06142396 2026-03-12
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Phase EARLY_PHASE1 Recruiting
NCT07391657 2026-03-12
DURGA-4
AstraZeneca
Phase 3 Recruiting
NCT06192979 2026-03-09
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Phase NA Recruiting
NCT06627309 2026-03-09
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
Recruiting
NCT05870917 2026-03-02
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06390319 2026-02-27
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT03850366 2026-02-24
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Henry Ford Health System
Phase 2 Recruiting
NCT03136146 2026-02-17
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04265872 2026-02-12
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
NCT04414475 2026-02-02
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Karyopharm Therapeutics Inc
Phase 2 Recruiting
NCT07297329 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd.
Phase 3 Recruiting
NCT04240054 2026-01-28
VICD
Medical College of Wisconsin
Phase 2 Recruiting
NCT05137054 2026-01-22
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
Phase 1 Recruiting